Ayala Pharmaceuticals Inc (ADXS)

[foggdogg]

Just spoke with Douglas Hulse from The Sage Group:

Since 1994, Sage has advised on well over $1 billion worth of M&A and licensing transactions for various pharmaceutical and biotechnology companies. For further information on The Sage Group, please visit their website located at www.sagehealthcare.com. Interested parties may contact R. Douglas Hulse at 908-231-9644 x704
http://ih.advfn.com/p.php?pid=nmona&cb=1244151211&article=37614719&symbol=NB%5EADXS

I asked Mr. Hulse for a progress report concerning licensing and he was kind enough to oblige me. In our discussion, 2 things became very clear. (1) That the ADXS11-001 "Flagship" vaccine Licensing is not what The Sage group is involved with. (2) The Sage Group is seeking Licensing for all the Advaxis platforms including HIV and Influenza constructs.

The Sage Group has put together a presentation for all platforms in Advaxis' pipeline. And is actively entertaining any interest generated by the presentation from all potential suitors. I asked if there had been any interest to date and Mr. Hulse said they were sifting through the various inquiries on the table which I'm thinking are very preliminary. Also, Mr. Hulse mentioned that as far as cancer vaccine companies in existence today go, ADXS is the cream of the crop out there.

My commentary:

Sage is working on a licensing deal that could lead to a M&A deal as Mr. Hulse said as much. Of course, if, in your quest to get a licensing deal in place and the potential partner says we would prefer to buy you out, well, you take the negotiations to another level. So licensing or buyout for all constructs is what Sage is working on. I asked for typical timeline on similar deals and got the standard 6 months to a 1 year response which I am sure it takes every bit of in most instances. Of course some could come earlier.

Now, keep in mind that the annual meeting that was postponed was in regards to the ADXS11-001 "Flagship" licensing and not the licensing that The Sage Group is diligently working towards.

Advaxis, Inc. (OTCBB: ADXS) is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.
Due to the potential materiality of the aforementioned event, Advaxis ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.
http://ih.advfn.com/p.php?pid=nmona&cb=1244150927&article=37355538&symbol=NB%5EADXS

I am also trying to get Mr. Moore's recent interview with TWST and will post it if I am successful. Have a great evening!

Fogg